- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Quarterly Financial Summary for Ipca Laboratories Limited**
Ipca Laboratories reported consolidated total income of ₹2,265.48 crore for the quarter ended December 31, 2024, representing a 9% decrease compared to the same period last year, driven by a decrease in domestic revenues. Standalone revenue from operations decreased by 8% to ₹1,662.68 crore, reflecting a decline in both branded and institutional formulations. However, export income remained stable at ₹680.91 crore, an increase of 6%, demonstrating strength in international markets.
The company's net profit surged by 38% year-over-year to ₹248.14 crore despite operational challenges, largely driven by improved cost management and a reduction in finance costs, down 37% to ₹10.17 crore. The earnings per share (EPS) witnessed a significant increase, reaching ₹10.55, marking a 95% rise from the previous year.
Operational expenses dropped by 11% to ₹1,324.57 crore, indicating effective cost control measures. The EBITDA margin also saw an uplift, moving to 19.87% as opposed to 16.10% in the previous year, indicating a strengthening operational efficiency.
From a strategic perspective, the focus appears to be on enhancing profitability through expense reduction and market expansion, especially in exports. Investor sentiment should lean towards a *buy* as the company appears well-positioned to recover and capitalize on future growth opportunities in both domestic and international segments.